FDA approves Roche ’s Hemlibra for haemophilia A without factor VIII inhibitors

Roche announced today that the US Food and Drug Administration (FDA) has approved Hemlibra ® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with haemophilia A without factor VIII inhibitors.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news